生物制药公司Immunic, Inc.宣布,其已获得一项欧洲关键专利授权,该专利将为Vidofludimus钙的相关给药方案提供重要保护。此项专利的授予进一步巩固了公司在开发该创新疗法方面的知识产权地位。
生物制药公司Immunic, Inc.宣布,其已获得一项欧洲关键专利授权,该专利将为Vidofludimus钙的相关给药方案提供重要保护。此项专利的授予进一步巩固了公司在开发该创新疗法方面的知识产权地位。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.